^
Association details:
| Biomarker: | PD-L1 elevation |
|---|---|
| Cancer: | Non Small Cell Lung Cancer |
| Drug: | Mekinist (trametinib) (MEK inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
2324P - Trametinib and PD-1 combined blockade impairs tumor growth and improves survival of KRAS-mutant lung cancer through Id1 downregulation
Published date:
10/16/2023
Excerpt:
In vivo experiments confirmed a synergistic therapeutic efficacy of the trametinib and anti-PD-1 combo, reducing tumor growth (p<0.05) and increasing mice survival (p<0.05), compared with either trametinib or immunotherapy alone...PD-L1 upregulation induced by Id1 blockade after trametinib treatment sensitized NSCLC cells to anti-PD-1 immunotherapy, blocking tumor growth and improving overall survival.
Secondary therapy:
PD1 inhibitor
